Health Professional Radio - Podcast

Daniel Shapiro, author of "The Thin Ledge: A Husband's Memoir of Love, Trauma, and Unexpected Circumstances" shares the reality of the fifteen years he spent living and caring for his wife, who suffered two massive brain hemorrhages and a personality change, while also single handedly raising their three young children. He discusses moving on and growing from trauma, moral issues, the struggle of a caregiver, and his perspective as a male caregiver. This book addresses questions that people living through unspeakable misfortunes may never mention, but almost always ask. ​​ #PersonalGrowth #HealingAfterTrauma Dan Shapiro is a member of the Board of Trustees of the Brain Research Foundation, a foundation that exists to accelerate discoveries of the human brain by funding pioneering neuroscience research. Dan’s three children co-founded the Young Leadership Board in 2016 and have raised more than $260,000 for BRF. Dan is a graduate of the University of Chicago Law School. A lifelong Chicagoan, he has practiced t

Dr. Bruce Bender, PhD, lead researcher and co-director of the Center for Health Promotion at National Jewish Health discusses recent research published in "The Journal of Allergy and Clinical Immunology: In Practice" about The Asthma Toolkit Bootcamp, a program that improved physician adherence to current guidelines, leading to fewer hospitalizations, emergency room visits, and decreased use of oral medications. #AsthmaToolkitBootcamp Dr. Bender is a member of the faculty at National Jewish Health, where he initiated the pediatric neuropsychology service. From this service, he began a research program designed to examine incidence and correlates of cognitive impairment in children with asthma, leading to a series of studies on the neuropsychological side effects of medications used to treat allergies and asthma. He has an ongoing research program that investigates health care behaviors that moderate asthma treatment effects, and the psychological disorders that undermine adherence. Dr. Bender is the head of t

Rami Levin, President and CEO of Saniona discusses Tesomet, the first and only investigational treatment for Hypothalamic Obesity (HO) to receive orphan drug designation. This marks a major milestone for the patient community as there are currently no medications specifically approved for HO. Patients living with this disease experience uncontrollable hunger and intractable weight gain, which is often complicated by depression, impulse control issues and increased risk of cardiovascular and metabolic disorders. This milestone builds on the orphan drug designation granted by the FDA earlier this year to Tesomet for the treatment of Prader-Willi Syndrome (PWS) and Saniona is preparing to initiate Phase 2b studies of Tesomet in HO and PWS in the second half of this year.​ #Saniona #HypothalamicObesity Rami Levin, President and Chief Executive Officer. Rami Levin (born 1969) is a seasoned biotech leader with over 24 years of experience in rare diseases and central nervous system disorders. Prior to joining Sanion

Sara Thomas, PhD, RD, registered dietician and research scientist at Abbott, discusses a new study from Abbott and The Ohio State University that was published in "Nutrients" that showed that adults with diabetes with low protein leads to physical limitations, lower overall diet quality, poorer nutrition density and more carbohydrates consumed. #Abbott #Nutrients Sara Thomas , PhD, RD is a registered dietitian and a research scientist supporting the Global Science team at Abbott. Sara provides clinical and scientific expertise for Abbott’s adult nutrition products and specializes in diabetes and oncology. Previously, Sara has worked in various roles in the field of nutrition including academic, government, and industry settings. Her previous nutrition research experience includes carotenoids, adult obesity, and dietary supplements. Sara earned her master’s degree and PhD in Nutrition Science and completed her dietetic internship at the Ohio State University and conducted her post-doctoral training at the USDA

Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company's blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an approach that is getting alot of attention right now. He talks about how this technology differs from current blood purification technologies and what the current treatment landscape looks like. #SigynTherapeutics #BloodPurificationTechnology #CytokineStorm James “Jim” Joyce has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. He is also an inventor or co-inventor underlying 18 pending or issued patents. Prior to establishing Sigyn Therapeutics, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, a therapeutic technol

Adam Sachs, co-founder and CEO of Vicarious Surgical, a company backed by Bill Gates and Vinod Khosla, discusses the company's Fantastic Voyage inspired-surgical robot that uses immersive reality to guide today's surgeons inside the body with new, groundbreaking technology that sets it apart from competitors. The system has received FDA Breakthrough Device designation. #VicariousSurgical #SurgicalRoboticsDisrupter Adam Sachs is CEO of Vicarious Surgical, a surgical robotics company he co-founded in 2014. Sachs leads the development and commercialization of the company’s surgical robots to increase the efficiency of procedures and improve patient outcomes. Prior to founding Vicarious Surgical, Sachs worked at Apple in manufacturing. He holds a Bachelor of Science in mechanical engineering from MIT and has worked for more than 11 years as a volunteer emergency medical technician for MIT EMS, an ambulance serving the MIT community.

Derek Wallace, Vice President and Dengue Global Program Lead at Takeda, discusses the first public presentation of long-term safety and efficacy results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate, TAK-003, and the launch of the company’s global HCP dengue education platform, Dengue Academy. #Dengue #DengueVaccine Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, Mr. Wallace leads the global program team in the development of Takeda’s dengue vaccine candidate (TAK-003). Mr. Wallace joined Takeda in September 2013 as Global Programme Medical Director responsible for the development of TAK-003 as well as Takeda’s enterovirus vaccine candidate.Mr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, Mr. Wallace held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur

Returning guest, Cathy Kuhn, PharmD, Director, Voice of the Customer at Updox, a complete healthcare communication platform for in-person and virtual care, discusses their recently released "Paperless Practice Playbook" with tips for providers on how to increase productivity, improve patient engagement and reduce burnout. She talks about why providers must eliminate paper in order to reduce the amount of time spent on administrative tasks for both provider and patients and how one practice saved more than 500 hours a year on administrative tasks by leveraging a paperless practice. #Productivity #PatientEngagement #ReduceBurnout Cathy Kuhn, PharmD, BCACP, FAPhA, is the Director of Strategy Consulting at Updox.  She is past president of the Ohio Pharmacists Association and current president of the American Pharmacist’s Association’s (APhA) Academy of Pharmacy Practice and Management and APhA board member. Cathy’s service to the profession has given her a front-row seat to a pharmacists’ positive impact, an

Dr. Cindy Jacobs, PhD, MD, President and Chief Medical Officer at Achieve Life Sciences discusses the grant that was awarded from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for the cessation of nicotine e-cigarette use. #AchieveLifeSciences Cindy Jacobs, Ph.D., M.D. · President & Chief Medical Officer, Achieve Life Sciences Inc. Dr. Jacobs is an experienced executive in drug development with expertise in several indications and over 30 years’ experience in Biotechnology/Pharmaceutical industry. Dr Jacobs has achieved regulatory success in several product approvals. Prior to joining Achieve Life Sciences in 2017, Dr. Jacobs served as OncoGenex’s Executive Vice President and Chief Medical Officer since August 2008, and had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and

Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer’s Association International Conference (AAIC); PRX012, Prothena’s next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer's Disease (AD).   He talks about the company's approach to addressing the AD global healthcare crisis. #Alzheimer #AAIC H​ideki Garren, M.D., Ph.D.​, Chief Medical Officer​. Dr. Garren has served as our Chief Medical Officer since April 2021. Before joining Prothena, between 2013 and 2021 Dr. Garren was with F. Hoffmann-La Roche Ltd. (Roche) & Genentech Inc. and most recently served as Vice President, Global Head of Neuroimmunology with responsibility for leading Roche’s Neuroimmunology franchise team. Prior to Roche, between 2011 and 2013, Dr. Garren held the role of Executive Director, Translational Medicine Expert in Neuroscience with Novartis Pharma. Dr. Garren also served as Co-F

Mike Rea, is founder of Protodigm, a contract skunkworks lab specializing in minimizing the risk of drug development by avoiding bias, premature specialization, and providing clients a universe of possibilities in which a drug could be brought  to market.   He talks about how the use of the skunkworks concept common in tech and engineering can innovate drug development. #Protodigm #DrugDevelopment Mike is the founder of Protodigm, a next generation CRO that innovates, invents, develops, and prototypes possibilities for drugs to be brought to market, as well as the CEO and founder of IDEA Pharma, a specialist in pharmaceutical product positioning and path-to-market strategies. He has delivered positioning and strategy for eight of the fifteen biggest drug launches in the last five years. After having been named to The Medicine Maker’s Global Power List 100 from 2017 to 2019, in 2020 and 2021 he was added to the Global Power List 20: the top 20 inspirational medicine makers in biopharmaceuticals.

As the most common type of non-cancerous tumors in women of reproductive age, uterine fibroids can cause physical symptoms, including heavy menstrual bleeding. Additionally, uterine fibroids can take a significant toll on quality of life, relationships and intimacy, employment, and create an overall reduced quality of well-being in a patient’s health.   Dr. Veronica Gillispie-Bell, Senior Site Lead and Section Head of Obstetrics and Gynecology  at Ochsner Kenner in New Orleans discusses heavy menstrual bleeding as a symptom of uterine fibroids, options in the treatment landscape, including ORIAHNN™, the first, non-surgical, oral medication developed specifically to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal patients.   She also shares how HCPs can open a dialogue with patients about their individual symptoms, lifestyle and treatment goals, and to address their concerns sooner rather than later. #UterineFibroids #ORIAHNN Veronica Gillispie-Bell, MD

Dr. ​Steve Roman​o​, ​MD, ​Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals discusses the results of their pivotal Phase 3 STRATA2016 clinical trial of StrataGraft ®, an investigational allogeneic cellularized scaffold product in development for the treatment of adult patients with deep partial-thickness burns. The data was published in "Burns" peer review journal (July 2021). It received FDA approval in July 2021 and can provide burn surgeons with an alternative biologic treatment option for patients with deep partial-thickness burns. #MallinckrodtPharmaceuticals #STRATA2016 Dr. Steven Romano is executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals. He has executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions, and is a member of Mallinckrodt’s executive committee. A board-certified psychiatrist, Dr. Romano has more than 20 years of experience in the pharmaceutical industry. Prior t

Nearly 1.8 million people globally die of lung cancer each year, more than the second and third most deadly cancers combined (colorectal and stomach cancer, respectively) because it is often detected and treated too late. Dr. Avrum "Avi" Spira, MD, MSc, Global Head of the Lung Cancer Initiative (LCI) at Johnson & Johnson, a renowned pulmonologist and lung cancer researcher, wants to make lung cancer a disease of the past. He discusses why early detection with lung cancer is key, what recent advancements in imaging, robotics and artificial intelligence have unlocked in new ways to screen for and access cancer, and how LCI is working to develop solutions to prevent, intercept and cure lung cancer. #LungCancer #LungCancerInitiative Avrum “Avi” Spira, MD, MSC, is the Global Head of the Lung Cancer Initiative (LCI) at Johnson & Johnson, which is developing solutions to prevent, intercept and cure lung cancer. Practicing medicine for more than 20 years, Dr. Spira leads a team of dedicated industry leaders a

Dr. Chris Anzalone, PhD, President and CEO of Arrowhead Pharmaceuticals discusses new positive patient-level data from their AROAAT2002 global Phase 2 study of ARO-AAT, an RNA therapeutic being co-developed by the company and Takeda, in patients with liver disease caused by alpha-1 antitrypsin deficiency (AATD).   He also talks about the company's RNAi platform. #ArrowheadPharmaceuticals #LiverDisease Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Repr

Dr. Arezou Khosroshahi​, ​MD, Associate Professor of Medicine at Emory University​ discusses the enrollment of the first patient in Horizon Therapeutics' Phase 2 trial to evaluate HZN-7734, ​a first- in-class, fully human monoclonal antibody to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system mistakenly attacks healthy cells and tissues. Of the 5 million people living with a form of lupus, SLE accounts for nearly 70 percent of cases and presents a tremendous unmet treatment need.​ #HorizonTherapeutics #SystemicLupusErythematosus Arezou Khosroshahi is an Associate Professor of Medicine in the division of Rheumatology. She joined Emory in 2012 and founded the IgG4-RD clinic at Emory. This clinic is one of the few in the United States to evaluate and treat patients with IgG4-RD with referral from all around the Southeast. She has been one of the initial investigators interested in understanding IgG4-RD since her fellowship at M

Dr. James Tursi, MD, Chief Scientific Officer of Ferring Pharmaceuticals discusses developments in microbiome-based therapeutics for the treatment of recurrent C. difficile (rCDI) infection. The current standard of care treatment for rCDI is currently antibiotics. While they are important, they do not restore the underlying health of the gut microbiome, nor can they stop C. diff​icile​ spores from growing back. He talks about what their late stage pivotal Phase 3 clinical trial results showed regarding mitigating recurrent C. difficile infection.​ ​The ​gut ​microbiome is an emerging area where biotherapeutics are being developed to address certain diseases and conditions.​ #FerringPharmaceuticals #ClostridioidesDifficileInfection Dr. James Tursi is responsible for U.S. Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance (PV), Project Planning and Regulatory Affairs. James collectively has over 30 years of experience in medicine and nearly 20 years in the pharmaceutical indust

Returning guest, Dr. Kaveh Safavi, Global Health Lead of Accenture Health, discusses the findings from their 2021 Digital Health Tech Vision report that surveyed 399 healthcare executives across six countries to better understand their view of the impact technology is having on the healthcare industry and what this means for the future. #AccentureHealth #DigitalHealthTechnology Kaveh Safavi, M.D., J.D., is a senior managing director at Accenture where he is responsible for leading, developing, and driving a growth strategy that differentiates Accenture’s offerings for providers, health insurers, and public and private health systems across the globe. A seasoned executive, Dr. Safavi brings more than three decades of leadership experience to Accenture Health. Prior to joining Accenture in 2011, Dr. Safavi led Cisco’s global healthcare practice. Before that, he was chief medical officer of Thomson Reuters’ health business, vice president of medical affairs at United Healthcare, and had leadership roles at Healt

Girish Navani, CEO and Cofounder of eClinicalWorks, a leader in healthcare IT solutions discusses PRISMA, the healthcare industry's first health information search engine that leverages a "one patient, one record" approach for fast and accurate decision-making that can be lifesaving. This platform helps to better know patients and provide more effective clinical care and can even cut patient wait times from approximately 30 minutes to 10 minutes. #eClinicalWorks #PRISMA Girish Navani helps set the company’s vision, leading efforts to grow and expand all aspects of the business, and actively manages its Research & Development pursuits. His efforts assist in securing eClinicalWorks as both a pioneer and leader in the healthcare IT industry. He was named to Boston Business Journal’s 2014 Power50 list of most influential people in Boston, honored as a 2010 Mass High Tech All-Stars honoree and received the Ernst & Young Entrepreneur Of The Year® 2009 Award in the Healthcare Technology category in New Engla

Returning guest, Dr. Larry Edwards, ​MD, MACP, MACR, rheumatologist and Chairman of the Gout Education Society discusses managing gout during the summer, with travel and get togethers, and how HCPs can prepare their patients to manage proper medications and lifestyle habits during this time. #GoutEducationSociety #ManagingGout #Gout Dr. N. Lawrence Edwards is Professor of Medicine, Division of Rheumatology and Clinical Immunology, as well as Program Director and Vice Chairman of the Department of Medicine at the University of Florida in Gainesville. Dr. Edwards obtained his undergraduate training at the University of Notre Dame and his medical degree from the University of Miami School of Medicine. He completed his training in Rheumatology at the Rackham Arthritis Research Center and the Clinical Research Center, University of Michigan in Ann Arbor where he remained on the faculty as Director of Education and Training in the Division of Rheumatology. In 1983 he moved to the University of Florida where he is t